An evaluation of ivosidenib for the treatment of IDH1 -mutant cholangiocarcinoma.

Ivosidenib is an excellent option for -mutant cholangiocarcinoma that progressed on first-line chemotherapy given its excellent tolerability and median OS benefit. However, a few questions remain unanswered - sequencing of targeted therapies, benefits of combining targeted therapy with systemic chemotherapy or with other treatment modalities, such as immunotherapy and localized therapies.